how to invest in digital currency, Reviews

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Zhonglu Co., Ltd.: The total amount of taxes and late fees paid is 15,430,100 yuan. Zhonglu Co., Ltd. announced that the company, as a limited partner of Zhonglu Advantage, received its cash asset distribution according to the resolution of Zhonglu Advantage Partner Meeting. In view of the above-mentioned asset allocation matters, the company strictly abides by the relevant regulations and adopts the principle of "tax after distribution". As required, it has declared and paid enterprise income tax of 11,770,500 yuan and late payment fee of 3,659,500 yuan, totaling 15,430,100 yuan. The late payment fee paid by the company will be included in the current profit and loss in 2024, which is expected to affect the company's net profit attributable to shareholders of listed companies in 2024 by about 3,659,500 yuan.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

Xia Yiping, CEO of Extreme Vietnam: I won't run away! Agreeing with employees' reasonable demands, communication with Baidu and Geely working groups has been established. The reporter learned from the inside of Extreme Yue Automobile that on the evening of December 12, Xia Yiping, CEO of Extreme Yue Automobile, informed all employees of the latest progress by means of synchronous news of flying books. Xia Yiping said: "Shanghai, the social security provident fund tax payment is completed; Beijing Jidu Technology has paid the provident fund before, because the system can't pay the social security tax tonight (December 12), and will go to the counter to pay it early tomorrow (December 13); Beijing jidu service, social security provident fund tax payment is completed; Wuhan, the social security provident fund tax payment is completed; Zhejiang, the provident fund has been paid before, and the social security tax will be paid tomorrow (December 13); In the remaining cities, the social security provident fund has been paid, and the individual tax will be paid tomorrow (December 13). " (national business daily)On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Zhengzhou Investment Holding Company increased its capital to 7.78 billion yuan, with an increase of about 121%. Tianyancha App shows that Zhengzhou Investment Holding Co., Ltd. has undergone industrial and commercial changes recently, adding Zhengzhou Development Investment Group Co., Ltd. as a shareholder, and its registered capital has increased from about 3.53 billion yuan to about 7.78 billion yuan, with an increase of about 121%. At the same time, many senior executives have changed. Zhengzhou Investment Holding Co., Ltd. was established in October 2005, and its legal representative is Yu Jianwei. Its business scope covers state-owned assets investment and management, real estate development and sales, and house leasing. Now Zhengzhou Zhongrongchuang Industrial Investment Co., Ltd. and the above-mentioned newly-added shareholders jointly hold shares.

The "hot" power of the ice and snow economy is infinite. The sales of ice and snow products in Yiwu are hot. With the new round of cold air coming, the cooling mode has been started again in many places across the country. The low temperature weather promotes the warming of ice and snow movement in many places, and the "heat" of ice and snow economy is booming. In Yiwu, Zhejiang, the sales of ice and snow products are hot. (Xinhua News Agency)Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.